Indian drugs giant Cipla said Friday it has slashed by up to 76 percent prices of generic medicines used to treat brain, lung and kidney cancer in what the company called a "humanitarian move".
May 4, 2012
0
0
A new Australian study led by SAHMRI and Flinders University has uncovered fundamental differences in how the AstraZeneca and Pfizer COVID-19 vaccines impact the immune system.
Feb 22, 2023
1
215
A correlation between a first dose of the AstraZeneca vaccine and a small but significant rise in cases of the serious neurological condition Guillain-Barré syndrome (GBS), has been identified by University College London ...
May 30, 2022
0
419
With COVID-19 community transmission on the rise once again, those aged over 50 are weighing up the benefits of being vaccinated against the virus with the very rare risk of blood clotting induced by the AstraZeneca vaccine.
May 27, 2021
0
7
Norwegian biologist Gro Amdam writes this in an email to ScienceNorway from the U.S., where she is professor at Arizona State University.
Apr 23, 2021
0
42
A woman who received an experimental coronavirus vaccine developed severe neurological symptoms that prompted a pause in testing, a spokesman for drugmaker AstraZeneca said Thursday.
Sep 10, 2020
0
16
(HealthDay)—Doctors might have figured out why AstraZeneca's COVID-19 vaccine may cause life-threatening blood clots in very rare cases.
Apr 9, 2021
0
187
Johnson & Johnson said Monday it will start delivering its single-shot COVID vaccine to Europe on April 19, giving the continent a boost as it struggles to speed up its vaccination drive.
Mar 29, 2021
0
4
The protection offered by the Oxford-AstraZeneca COVID-19 vaccine declines after three months of receiving two doses, a study says.
Dec 20, 2021
0
213
AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S. study, a finding that could help rebuild public confidence in the shot around the world ...
Mar 22, 2021
0
100
AstraZeneca plc (LSE: AZN, OMX: AZN, NYSE: AZN), is a large Anglo-Swedish pharmaceutical company formed on 6 April 1999 by the remerger of Swedish Astra AB and British Zeneca Group plc. Zeneca had been part of Imperial Chemical Industries, as 3 divisions that were spun off from ICI on 1 June 1993. The Company is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.
This text uses material from Wikipedia, licensed under CC BY-SA
